时代:History is about to repeat itself, this time in the biotech sector

billwanhua

本站元老
注册
2005-07-07
消息
16,669
荣誉分数
5,467
声望点数
373

In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical industry to China. Though we have long stood as the global leader in biotechnology, we are now at risk of losing that position, just as we did with semiconductors a generation ago.

American innovation brought about the semiconductor revolution. For decades, we supplied the world with those innovations, too: U.S. manufacturers produced nearly 40% of all semiconductors in 1990. Today, that number is hardly over 10%. And while the Chinese chip industry has long lagged behind global leaders, China has spent billions catching up and is expected to have captured nearly 25% of the worldwide chip manufacturing market by 2030.
 

U.S. drugmaker Pfizer (PFE.N), opens new tab said it would license an experimental cancer treatment from China's 3SBio Inc (1530.HK), paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

辉瑞投资48亿美元买医药使用权,预付12.5亿,真有钱

 
最后编辑:
后退
顶部